Davis CB - Search Results

1

Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.

Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR. Davis CB, et al. Drug Metab Dispos. 1995 Oct;23(10):1028-36. Drug Metab Dispos. 1995. PMID: 8654189

2

Disposition of metabolically labeled recombinant soluble CD4 (sT4) in male Sprague-Dawley rats following intravenous and subcutaneous administration.

Davis CB, Boyle KE, Urbanski JJ, Paradysz RT, Fong KL. Davis CB, et al. Drug Metab Dispos. 1992 Sep-Oct;20(5):695-705. Drug Metab Dispos. 1992. PMID: 1358574

3

Disposition of growth hormone-releasing peptide (SK&F 110679) in rat and dog following intravenous or subcutaneous administration.

Davis CB, Crysler CS, Boppana VK, Fong KL, Joseph GL, Urbanski JJ, Macia RA, Rhodes GR. Davis CB, et al. Drug Metab Dispos. 1994 Jan-Feb;22(1):90-8. Drug Metab Dispos. 1994. PMID: 8149896 Clinical Trial.

4

Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.

Hepburn TW, Davis CB, Urbanski JJ, Smith BR, Schaefer WH, Carbonaro MA, Bugelski PJ. Hepburn TW, et al. Among authors: davis cb. Drug Metab Dispos. 1995 Oct;23(10):1044-50. Drug Metab Dispos. 1995. PMID: 8654191

5

Disposition of metabolically radiolabeled CE9.1--a macaque-human chimeric anti-human CD4 monoclonal antibody--in transgenic mice bearing human CD4.

Davis CB, Garver EM, Kwok DC, Urbanski JJ. Davis CB, et al. Drug Metab Dispos. 1996 Sep;24(9):1032-7. Drug Metab Dispos. 1996. PMID: 8886616

6

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.

Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. Everitt DE, et al. Among authors: davis cb. J Infect Dis. 1996 Sep;174(3):463-9. doi: 10.1093/infdis/174.3.463. J Infect Dis. 1996. PMID: 8769601 Clinical Trial.

7

Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.

Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LA, Davis CB. Zia-Amirhosseini P, et al. Among authors: davis cb. J Pharmacol Exp Ther. 1999 Dec;291(3):1060-7. J Pharmacol Exp Ther. 1999. PMID: 10565825

8

Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.

Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. Benincosa LJ, et al. Among authors: davis cb. J Pharmacol Exp Ther. 2000 Feb;292(2):810-6. J Pharmacol Exp Ther. 2000. PMID: 10640322

9

Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.

Sharma A, Davis CB, Tobia LA, Kwok DC, Tucci MG, Gore ER, Herzyk DJ, Hart TK. Sharma A, et al. Among authors: davis cb. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41. J Pharmacol Exp Ther. 2000. PMID: 10734150

10

Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.

Hepburn TW, Totoritis MC, Davis CB. Hepburn TW, et al. Among authors: davis cb. Rheumatology (Oxford). 2003 Jan;42(1):54-61. doi: 10.1093/rheumatology/keg030. Rheumatology (Oxford). 2003. PMID: 12509613 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters